copanlisib   Click here for help

GtoPdb Ligand ID: 7875

Synonyms: Aliqopa® | BAY 80-6946 | BAY80-6946
Approved drug PDB Ligand
copanlisib is an approved drug (FDA (2017))
Compound class: Synthetic organic
Comment: Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor [2], preferentially inhibiting PI3Kα and PI3Kβ, and with significant antineoplastic activity [3]. The compound has less potent mTOR activity.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 142.01
Molecular weight 480.22
XLogP 1.76
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1c(OCCCN2CCOCC2)ccc2c1nc(=NC(=O)c1cnc(nc1)N)n1c2NCC1
Isomeric SMILES COc1c(OCCCN2CCOCC2)ccc2c1nc(=NC(=O)c1cnc(nc1)N)n1c2NCC1
InChI InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27)
1. EMA. 
Copanlisib orphan designation.
Accessed on 15/04/2019. Modified on 15/04/2019. EMA,
2. Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, Fracasso PR, Wilkie DP, Hentemann M, Wilhelm SM et al.. (2013)
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.
Mol Cancer Ther, 12 (11): 2319-30. [PMID:24170767]
3. No authors listed. (2014)
Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.
Clin Adv Hematol Oncol, 12 (2 Suppl 5): 14-6. [PMID:24852792]